Nuwellis (NASDAQ:NUWE) Posts Earnings Results

Nuwellis (NASDAQ:NUWE) announced its earnings results on Thursday. The company reported ($5.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($122.85) by $117.04, Zacks reports. Nuwellis had a negative net margin of 123.38% and a negative return on equity of 623.14%.

Here are the key takeaways from Nuwellis’ conference call:

• Third-quarter revenue was flat at $2.2 million year over year, though management said growth was about 20% excluding roughly $400,000 of prior-year back-order shipments. Revenue for the first nine months rose 13% to $6.6 million.
• Gross margin increased to 70% from 65%, operating expenses declined year over year, and operating loss improved 24% to $2.1 million. The company ended September with $8.3 million in cash and said its runway extends through the second quarter of 2027.
• Pediatric sales grew 20% in the quarter and 26% year to date; console sales were up 88% year to date, although quarterly console sales fell to eight from 12. Nuwellis submitted a 510(k) application seeking to expand Aquadex use to children weighing as little as five kilograms; FDA clearance is not yet assured.
• Nuwellis added distribution agreements for two pediatric-care products, including Zorro-Flow, which it expects to launch in early 2027. It also expects to launch its SmartView interface in the first quarter of 2027 and Pressure IQ in the first half of 2027.

Nuwellis Stock Performance

Shares of NASDAQ NUWE traded down $0.35 during trading hours on Thursday, hitting $5.17. 21,476 shares of the stock were exchanged, compared to its average volume of 340,863. The company’s fifty day simple moving average is $6.10 and its two-hundred day simple moving average is $215.89. The company has a market cap of $2.79 million, a PE ratio of -0.00 and a beta of 0.03. Nuwellis has a 1-year low of $2.52 and a 1-year high of $1,556.07.

Analysts Set New Price Targets

NUWE has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Nuwellis to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Nuwellis in a research report on Monday, September 21st. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Nuwellis presently has an average rating of “Sell”.

Nuwellis Company Profile

Nuwellis, Inc. is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated. Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.